Proposal for a New Protocol for the Management of Immune Thrombocytopenia (ITP).
Adv Ther
; 39(6): 2287-2291, 2022 06.
Article
in English
| MEDLINE | ID: covidwho-1782984
ABSTRACT
For many decades immune thrombocytopenia (ITP) was managed using therapies which had not undergone randomised clinical trials and included corticosteroids, immune suppression or splenectomy. These older therapies are associated with an increase in morbidity and mortality. These empirical therapies have variable efficacy and well-described side effects for many patients with minimal benefit to the patient. Over the past 10 years there has been a shift away from immune suppression and non-evidence-based therapies towards using treatments with reduced or no immune suppression with an increasing reliance on the recently developed and approved thrombopoietin receptor agonists. The recent COVID-19 pandemic has made it more urgent that we develop non-immune suppressive strategies for ITP. In this commentary we describe our proposal for a contemporary approach to the management of ITP in adults that is based on our hospital practices and published guidelines.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Thrombocytopenia
/
Purpura, Thrombocytopenic, Idiopathic
/
COVID-19
Type of study:
Diagnostic study
/
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Limits:
Adult
/
Humans
Language:
English
Journal:
Adv Ther
Journal subject:
Therapeutics
Year:
2022
Document Type:
Article
Affiliation country:
S12325-022-02133-1
Similar
MEDLINE
...
LILACS
LIS